| Literature DB >> 24485902 |
Kathryn Futrega1, Myfanwy King1, William B Lott1, Michael R Doran2.
Abstract
Type 2 diabetes is the epidemic of our generation, and diabetic foot ulcers (DFUs) are a major complication. Although DFU formation itself can indicate disease progression, the failure to effectively treat ulcers contributes further to a decay in patient quality of life and increased mortality. Herein we discuss the development of next-generation DFU therapies including: (i) topical growth factors, (ii) scaffolds, and (iii) cellular therapies. Individually these therapies have yielded measurable but modest improvements in DFU repair. Because DFUs arise as a result of multiple biochemical deficiencies, a singular treatment modality is unlikely to be effective. Next-generation DFU technologies must be combined to address effectively the complex underlying pathology and enable reliable DFU repair.Entities:
Keywords: diabetes; diabetic foot ulcers; growth factors; mesenchymal stem/stromal cells; scaffolds
Mesh:
Substances:
Year: 2014 PMID: 24485902 DOI: 10.1016/j.molmed.2013.12.004
Source DB: PubMed Journal: Trends Mol Med ISSN: 1471-4914 Impact factor: 11.951